Next Article in Journal / Special Issue
Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
Previous Article in Journal
Novel Treatment Targets Based on Insights in the Etiology of Depression: Role of IL-6 Trans-Signaling and Stress-Induced Elevation of Glutamate and ATP
Previous Article in Special Issue
Psychotropic Drugs for the Management of Chronic Pain and Itch
Review

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

by 1,* and 1,2
1
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
2
German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(3), 114; https://0-doi-org.brum.beds.ac.uk/10.3390/ph12030114
Received: 1 July 2019 / Revised: 23 July 2019 / Accepted: 26 July 2019 / Published: 29 July 2019
(This article belongs to the Collection The Story of Successful Drugs and Recent FDA-Approved Molecules)
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera® combines the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors. As a result, DNA single- and double-strand breaks are provoked, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions. View Full-Text
Keywords: Lutathera®, [177Lu]Lu-DOTA-TATE; thera(g)nostics; peptide receptor radionuclide therapy (PRRT); somatostatin receptor (SSTR); neuroendocrine tumors (NET) Lutathera®, [177Lu]Lu-DOTA-TATE; thera(g)nostics; peptide receptor radionuclide therapy (PRRT); somatostatin receptor (SSTR); neuroendocrine tumors (NET)
Show Figures

Figure 1

MDPI and ACS Style

Hennrich, U.; Kopka, K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals 2019, 12, 114. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12030114

AMA Style

Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals. 2019; 12(3):114. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12030114

Chicago/Turabian Style

Hennrich, Ute, and Klaus Kopka. 2019. "Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy" Pharmaceuticals 12, no. 3: 114. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12030114

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop